If you are attending Oppenheimer’s Novel Targets in Immunology Summit in NY next week, you can catch our President and CEO Nancy Whiting participate in a panel entitled “Novel Immunological Mechanisms For Dermatological Disorders,” as well as both Nancy and our Head of R&D Ajay Nirula for one-on-one meetings. #OPCOImmunology
About us
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. Its most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis inflammatory bowel disease, and others. The company is advancing another program with an undisclosed non-STAT SH2 domain target that also plays a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at https://recludixpharma.com.
- Website
-
http://www.recludixpharma.com
External link for Recludix Pharma
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Recludix Pharma
Updates
-
This #PRIDEMonth, we recognize the many accomplishments and contributions of the LGBTQIA+ community, and we also reflect on the right of being able to express yourself without prejudice. At Recludix, inclusion is essential, and diversity is power.
-
-
We’re excited to have data on our oral STAT3 small molecule inhibitors be featured in a plenary presentation today at the Society for Investigative Dermatology (SID) Annual Meeting. Read more: https://lnkd.in/gidksMyd
-
-
Our Head of R&D Ajay Nirula and our CBO Matthew Caldemeyer will be hosting meetings at the BIO International Convention in San Diego. Contact us to meet: https://lnkd.in/eF56CSgp
-
-
Our CEO Nancy Whiting and CBO Matthew Caldemeyer are participating in the Wells Fargo Private Biotech Symposium. If you would like to connect, contact us! https://lnkd.in/eF56CSgp
-
-
On #AdminProfessionalsDay, we are spotlighting Tracy Bychowski! We recognize and thank you for your hard work and dedication!
-
-
We are delighted to welcome Ajay, who joins us as EVP and Head of R&D with extensive expertise in immunology and over two decades of discovery and development experience, most recently as the SVP and Immunology Therapeutic Area Head for Eli Lilly. Read more about Ajay Nirula here: https://lnkd.in/ebpa3gN5
-
-
What do you get when you combine volunteering, food donation and creativity? A mini golf course made up of canned goods, of course! Thank you to our Recludix employees, who are always eager to get involved in the community and enjoy the occasional team-building competition. #NationalVolunteerMonth
-
-
With millions of people living with an autoimmune disease, the impact to individuals, families and society is significant. Our team is working on oral therapies to inhibit disease-driving pathways in a novel way, and we are hopeful our therapies will make a difference for many patients. You can learn more about autoimmune diseases and #AutoimmuneAwarenessMonth at https://autoimmune.org/.